EPISODE · Oct 25, 2009 · 13 MIN
Podcast 62: A conversation with Jane Kim about cost-effectiveness of vaccinating women with HPV vaccine after age 30.
from Clinical Conversations · host NEJM Group
The FDA seems set to announce a decision about vaccinating women past age 25 for HPV. A paper in the Annals of Internal Medicine this week indicates that such a strategy wouldn’t be cost-effective. Don’t be put off by “cost-effectiveness” or by the fact that we actually discuss “QALY”s. It’s all good. We’ve got Harvard School of Public Health’s Jane Kim to guide your interviewer through the QALY thicket, and she’s a great guide. Contact us at 1-617-440-4374 or write to [email protected]. This week’s links: NEWS: Aldosterone Antagonists Underused in Heart Failure ACP Issues Guidelines on Hormonal Testing and Pharmacologic Management of Erectile Dysfunction Ketorolac for Injection Recalled Intensified BP Control Benefits Kids with Chronic Kidney Disease INTERVIEW: Adding HPV Vaccination to U.S. Cervical Screening Isn’t Cost-Effective After Age 30 The post Podcast 62: A conversation with Jane Kim about cost-effectiveness of vaccinating women with HPV vaccine after age 30. first appeared on Clinical Conversations.
Embed this episode
What this episode covers
The FDA seems set to announce a decision about vaccinating women past age 25 for HPV. A paper in the Annals of Internal Medicine this week indicates that such a strategy wouldn’t be cost-effective. Don’t be put off by “cost-effectiveness” or by the fact that we actually discuss “QALY”s. It’s all good. We’ve got Harvard […]
Ready to play
Podcast 62: A conversation with Jane Kim about cost-effectiveness of vaccinating women with HPV vaccine after age 30.
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.